newsfilter
← Latest News
GlobeNewswire·

Silexion Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update

Israeli Ministry of Health approved the initiation of Silexion's Phase 2/3 clinical trial of SIL204 in locally advanced pancreatic cancer Clinical Trial Application subsequently submitted to Germany through the EU